We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
Corbus Pharmaceuticals Holdings, Inc.는 임상 단계 회사로서 암 및 비만 치료제를 개발하고 상용화합니다. 파이프라인에는 암세포의 Nectin-4 발현을 표적으로 하여 monomethyl auristatin E라는 세포독성 약물을 방출하는 항체-약물 접합체인 CRB-701과 비만 치료를 위한 말초 제한성 cannabinoid type-1 수용체 역작용제인 CRB-913이 있습니다. 이 회사는 2009년에 설립되었으며 매사추세츠주 Norwood에 본사를 두고 있습니다.